Panel Discussion: Selecting the “Right” Tumor Model Amid New Regulatory Pressures – What Truly Drives Predictive Value, Confidence & Decision Making?

• Exploring how drug developers define the “right” tumor model for each decision point: clarifying what level of biological fidelity, readout quality, and mechanistic insight is truly needed to drive confident progression
• Understanding how in silico, in vitro, and in vivo systems complement one another, and when single‑model data is sufficient versus when convergence across multiple platforms is required to strengthen internal decision‑making
• Examining how well different models correlate with real clinical outcomes and what evidence is still needed for regulators and developers to fully trust emerging technologies as credible, decision‑enabling tools

Speakers:

Isabel Jerchel-Furau

Associate Principal Scientist

Bayer

Violet Young

Senior Associate - Research

Mariana Oncology

Sowmya Balasubramanian

Translational Science Senior Scientist (Non-Clinical Biomedical Sciences)

Astellas

Athanasia (Nasia) Apostolou

Research Senior Scientist

Takeda